Welcome to the InfoSci Platform
Reference Hub2
Is China Catching Up?: Health-Related Applications of Biotechnology

Is China Catching Up?: Health-Related Applications of Biotechnology

Petr Hanel
Copyright: © 2017 |Pages: 56
ISBN13: 9781522510406|ISBN10: 1522510400|EISBN13: 9781522510413
DOI: 10.4018/978-1-5225-1040-6.ch016
Cite Chapter Cite Chapter

MLA

Hanel, Petr. "Is China Catching Up?: Health-Related Applications of Biotechnology." Comparative Approaches to Biotechnology Development and Use in Developed and Emerging Nations, edited by Tomas Gabriel Bas and Jingyuan Zhao, IGI Global, 2017, pp. 465-520. https://doi.org/10.4018/978-1-5225-1040-6.ch016

APA

Hanel, P. (2017). Is China Catching Up?: Health-Related Applications of Biotechnology. In T. Bas & J. Zhao (Eds.), Comparative Approaches to Biotechnology Development and Use in Developed and Emerging Nations (pp. 465-520). IGI Global. https://doi.org/10.4018/978-1-5225-1040-6.ch016

Chicago

Hanel, Petr. "Is China Catching Up?: Health-Related Applications of Biotechnology." In Comparative Approaches to Biotechnology Development and Use in Developed and Emerging Nations, edited by Tomas Gabriel Bas and Jingyuan Zhao, 465-520. Hershey, PA: IGI Global, 2017. https://doi.org/10.4018/978-1-5225-1040-6.ch016

Export Reference

Mendeley
Favorite

Abstract

The chapter examines whether Chinese health-related biotechnology is catching up with leaders in the field. The approach is inspired by Malerba's Sectoral System of Innovation and Production, complemented by Mathew's insight into strategies for latecomer firms. The results show that Chinese scientists are quickly catching up in the output of scientific publications. However, the basic research remains insufficient for the development of a sustainable, innovative industry. The industrial production of biotechnology-based manufacturing of drugs and medical devices is growing slower than their knowledge base. Most firms still manufacture under license or contract low-value “me too” generic pharmaceutical and biosimilar ingredients medicines. The intensity of R&D and patenting in China increased dramatically, especially in the foreign-invested firms but China's share of biotechnology patenting in the US, EPO and Japan are very low. In summary, Chinese biotechnology ‘industry' is catching up with the West, but it has a long way to go.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.